Evotec SE is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Evotec SE in the market include other leading pharmaceutical and biotechnology companies such as Johnson & Johnson, Roche Holding AG, Novartis AG, and Pfizer Inc. These companies also operate in the drug discovery and development sector, focusing on research and providing innovative solutions for various diseases and conditions. Evotec SE competes with them in terms of developing new drugs, advancing research technologies, and partnering with pharmaceutical companies for collaborations and licensing agreements.

Evotec SE, a renowned German biotechnology company, has an intriguing history and background marked by remarkable achievements. Established in 1993, Evotec started as a drug discovery and development firm. It has since evolved into a global leader, offering innovative solutions to the pharmaceutical and biotechnology industries. With a relentless commitment to scientific excellence and cutting-edge technologies, Evotec has built strong partnerships with prominent companies worldwide. Leveraging its expertise in drug discovery, preclinical development, and clinical manufacturing, Evotec has successfully delivered multiple therapies to the market. The company's collaborative approach, combined with its diverse portfolio and exceptional track record, sets Evotec SE apart as a compelling and trusted investment opportunity.

Evotec SE, a leading drug discovery and development company, has achieved several significant milestones. Over the years, the company has established strategic partnerships with renowned pharmaceutical and biotechnology firms, including top-tier organizations such as Bayer, Bristol-Myers Squibb, and Sanofi. Evotec's collaborations have resulted in the successful exploration and development of innovative therapies for various diseases. Furthermore, the company has consistently demonstrated strong financial growth and has been recognized with prestigious industry awards. Evotec SE's dedication to advancing drug discovery, fostering collaborations, and delivering breakthrough therapies has solidified its position as a prominent player in the pharmaceutical industry.

Evotec SE is primarily present in various countries and regions worldwide. The company has a global presence, with key operations and offices located in Germany, the United States, France, the United Kingdom, and Japan. Evotec SE has established strong footholds and partnerships in these regions, allowing it to extend its expertise and services internationally. With its diversified presence, Evotec SE continues to expand its reach across different markets, enabling the company to cater to a wider customer base and maintain its position as a leading provider in the biotechnology and pharmaceutical industry.

Evotec SE represents a strong set of values and a clear corporate philosophy. The company prioritizes innovation, excellence, and collaboration in its pursuit of advancing drug discovery and development. Evotec fosters a culture of integrity, professionalism, and ethical practices. With a focus on delivering value to its partners and shareholders, Evotec emphasizes long-term sustainable growth. Through its unique capabilities, scientific expertise, and cutting-edge technologies, Evotec aims to accelerate research and development, enabling the discovery of ground-breaking therapies to improve lives and address unmet medical needs. The company's commitment to scientific excellence and its collaborative approach have made Evotec a trusted and respected name in the biotechnology industry.

Analysts currently set an average price target of 9,07 EUR for the Evotec stock (median: 9,89 EUR), implying +164,2 % versus the latest price. The consensus is based on 13 analyst ratings.

Evotec Analyytikkojen kursstavoitteet 2026

13 analysts currently rate the Evotec stock: 9 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Evotec to generate revenue of 599,66 M EUR and earnings per share of −1,01 EUR.

Evotec Analyytikkojen kursstavoitteet 2026

The Evotec share (EVT.DE) is listed on 14 stock exchanges, including: NASDAQ (EVOTF), XETRA (EVT.DE), Frankfurt (EVT.F), München (EVT.MU), Stuttgart (EVT.SG), Düsseldorf (EVT.DU), Hamburg (EVT.HM), London (0IRF.L).

The Evotec SE is an innovative company in the biopharmaceutical industry based in Hamburg, specializing in the fields of science and technology. With a unique business model, Evotec offers its customers worldwide a comprehensive portfolio of services and products. These include drug discovery, preclinical development and optimization, drug manufacturing, and clinical development services. Through these different areas, Evotec provides its customers with a complete value chain from drug discovery to clinical development. One example is the Discover & Evotec platform, which combines data analysis, artificial intelligence, and experimental biology. This platform enables the discovery and optimization of new drug candidates, accelerating drug development. The platform is used by numerous partners, including the David H. Murdock Research Institute, the Fraunhofer Institute's Screening Center, the Helmholtz Association, and public institutions. In addition, Evotec is involved in the development of drug lifecycles in various therapeutic areas, including neuroscience, oncology, metabolic diseases, infections, and inflammations. The company has achieved several important milestones in the industry and is currently developing several innovative drugs in collaboration with leading pharmaceutical companies. Another important product in Evotec's portfolio is the "Indigo" software platform. This digitized platform allows for automated pipeline detection and screening, as well as predictive modeling of drugs. Indigo significantly accelerates drug development and improves the accuracy and speed of drug discovery, ultimately leading to better treatment of diseases. Evotec sees itself as a long-term, strategic, and trusted partner for its customers, aiming to accelerate the development of important drugs to improve people's lives worldwide. In fact, the company has had great success in recent years in developing drugs for Ebola and malaria. To further promote growth, Evotec also enters into partnerships and acquisitions to expand its portfolio and reach. In recent years, the company has formed partnerships with leading industry companies such as Sanofi, Celgene, and Bayer to develop innovative drugs. In summary, thanks to its innovative business model, Evotec SE plays an important role in the biopharmaceutical industry. Its wide range of services and products in various therapeutic areas enables customers to accelerate drug discovery and development. Evotec will continue to strive for significant medical advancements and make a positive impact on people's lives. Evotec SE is an innovative company in the biopharmaceutical industry and specializes in science and technology. It offers a comprehensive portfolio of services and products to customers worldwide. The company's various divisions include drug discovery, preclinical development, drug manufacturing, and clinical development. Examples of their services include the Discover & Evotec platform, which combines data analysis, artificial intelligence, and experimental biology to discover and optimize new drugs. Evotec is involved in the development of drugs in various therapeutic areas such as neuroscience, oncology, metabolic diseases, infections, and inflammations. Its Indigo software platform automates pipeline detection and screening, as well as predictive modeling of drugs. Evotec aims to be a long-term, strategic partner for their customers and has achieved milestones in drug development. They also partner with companies like Sanofi, Celgene, and Bayer to develop innovative drugs. Overall, Evotec is a key player in the biopharmaceutical industry and aims to make a positive impact on people's lives through their services and products.

odotettu liikevaihto Evotec on 599,66 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Evotec on −179,65 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Evotec:n hinta-voitto-suhde (P/E) on tällä hetkellä −3,40. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Evotec-osakkeen arvostusta.

Evotec:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,02. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Evotec-osakkeen arvostuskennuslukuna.

Evotec:n Eulpool-laatuscore on 2/10.

Evotec:n ISIN on DE0005664809. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Evotec:n WKN on 566480. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Evotec:n ticker on EVT.DE. Tämä pörssinoteeraus käytetään Evotec-osakkeiden kauppaan pörssissä.

Evotec maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Evotec kuuluu sektoriin 'Terveydenhuolto'.

Evotec:n osingot jaetaan valuutassa EUR.